Patient Testimonials In Web Ads Continue To Be Target Of FDA Warning Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
Citation of video for J&J’s Ultram ER is reminiscent of letter to Shire for Adderall XR sent last fall.
You may also be interested in...
Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says
Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.
Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says
Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.
FDA Chief Hamburg Says Rx Ads Need Broader Disease Information
New commissioner notes FDA has limited authority in an overloaded media landscape as drug advertising again becomes a target on Capitol Hill.